Frequency of SPAD in Adult Patients
Condition(s) studied
Investigational drug(s) / intervention(s)
Diagnosis of SPAD using immunization with PPV23: Diagnosis of SPAD using immunization with PPV23
Study summary
The DETECT study aims to demonstrate the importance of detecting SPAD in adult patients with recurrent benign and/or severe unexplained bacterial upper/lower respiratory tract infections. Unlike children in whom the deficit may be transient, long-term strategies are warranted in SPAD adult patients to prevent severe infections and lung disability. Beyond the diagnosis of this still unrecognized PID in adult patients, the investigators want to assess the impact of prophylactic antibiotics or IgRT on infections prevention and on quality of life in adult patients with the most severe clinical phenotypes, recurrent infections with high frequency of antibiotics take and/or recurrent infections with complications like bronchiectasis and/or severe infections requiring hospitalizations.
Eligibility
Primary outcome measure(s)
- To assess the frequency of SPAD in adult patients with unexplained recurrent bacterial respiratory infections — 4 to 8 weeks after immunization
Diagnosis of SPAD according to the AAAAI proposed consensus criteria for an impaired selective response to PS using immunization with PPV23 and assessment of anti-PnPS IgG response by the serotype-specific WHO-standardized ELISA 4 to 8 weeks after immunization
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Lille University Hospital | Lille | France | Recruiting |
More University Hospital, Lille trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05664035 on ClinicalTrials.gov ↗ ← All trials in France